1. Assessment of overall survival in glioma patients as predicted by metabolomic criteria
- Author
-
Sebastián Cerdán, Pilar López-Larrubia, Maria L Gandía-González, Laura Barrios, Pablo García Feijoo, Alexis Junnior Palpan, Juan Solivera, José M. Roda, Instituto de Salud Carlos III, Comunidad de Madrid, and Junta de Andalucía
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Poor prognosis ,Multivariate analysis ,overall survival ,lcsh:RC254-282 ,03 medical and health sciences ,0302 clinical medicine ,Metabolomics ,Internal medicine ,Glioma ,glioma ,Biopsy ,medicine ,Overall survival ,Metabolomic profile ,High resolution proton magnetic resonance spectroscopy ,Original Research ,classification decision tree ,Classification decision tree ,medicine.diagnostic_test ,Phosphorylcholine ,business.industry ,Total creatine ,metabolomic profile ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,high resolution proton magnetic resonance spectroscopy ,030104 developmental biology ,030220 oncology & carcinogenesis ,business - Abstract
© 2019 Gandía-González, Cerdán, Barrios, López-Larrubia, Feijoó, Palpan, Roda and Solivera., [Objective]: We assess the efficacy of the metabolomic profile from glioma biopsies in providing estimates of postsurgical Overall Survival in glioma patients., [Methods]: Tumor biopsies from 46 patients bearing gliomas, obtained neurosurgically in the period 1992–1998, were analyzed by high resolution 1H magnetic resonance spectroscopy (HR- 1H MRS), following retrospectively individual postsurgical Overall Survival up to 720 weeks., [Results]: The Overall Survival profile could be resolved in three groups; Short (shorter than 52 weeks, n = 19), Intermediate (between 53 and 364 weeks, n = 19) or Long (longer than 365 weeks, n = 8), respectively. Classical histopathological analysis assigned WHO grades II–IV to every biopsy but notably, some patients with low grade glioma depicted unexpectedly Short Overall Survival, while some patients with high grade glioma, presented unpredictably Long Overall Survival. To explore the reasons underlying these different responses, we analyzed HR-1H MRS spectra from acid extracts of the same biopsies, to characterize the metabolite patterns associated to OS predictions. Poor prognosis was found in biopsies with higher contents of alanine, acetate, glutamate, total choline, phosphorylcholine, and glycine, while more favorable prognosis was achieved in biopsies with larger contents of total creatine, glycerol-phosphorylcholine, and myo-inositol. We then implemented a multivariate analysis to identify hierarchically the influence of metabolomic biomarkers on OS predictions, using a Classification Regression Tree (CRT) approach. The CRT based in metabolomic biomarkers grew up to three branches and split into eight nodes, predicting correctly the outcome of 94.7% of the patients in the Short Overall Survival group, 78.9% of the patients in the Intermediate Overall Survival group, and 75% of the patients in the Long Overall Survival group, respectively., [Conclusion]: Present results indicate that metabolic profiling by HR-1H MRS improves the Overall Survival predictions derived exclusively from classical histopathological gradings, thus favoring more precise therapeutic decisions., This work was supported in part by grants PI2017/00361 from Instituto de Investigación Carlos III to JR, grant B2017/BMD-3688 from the Community of Madrid to JR and SC, and grant PI-0143-2016 from the Regional Ministry of Health of the Regional Government of Andalucía to JS.
- Published
- 2019